BP vs CLB
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BP's Advanced Deterministic Scorecard shows a Piotroski F-Score of 6/9, indicating stable financial health, but the absence of an Altman Z-Score limits distress risk assessment. The stock trades at a significant premium to its Graham Number ($7.35) and even the growth-based intrinsic value ($18.88), currently priced at $36.53, driven by high forward earnings expectations. While profitability metrics and dividend yield are attractive, elevated valuation multiples, inconsistent earnings surprises, and a dangerously high payout ratio of 315% raise sustainability concerns. Analysts recommend a 'buy' with a target of $38.73, supported by strong insider sentiment, though no insider transactions have occurred recently.
CLB exhibits a concerning divergence between its current market price ($17.45) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health. The stock is trading at a significant premium to both its Graham Number ($9.04) and Intrinsic Value ($4.41), while experiencing a sharp YoY earnings decline of 31.60%. Despite a strong 1-year price rally, the underlying fundamentals—specifically the negative earnings growth and bearish technical trend—suggest the current valuation is unsustainable.
Compare Another Pair
BP vs CLB: Head-to-Head Comparison
This page compares BP p.l.c. (BP) and Core Laboratories Inc. (CLB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.